Generic Capsules Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Generic capsules plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹9.9 crore - ₹226 crore CapEx this DPR captures:

• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The capsule manufacturing and generic drug plant landscape in India is bifurcated into an organized sector and an unorganized sector. The organized sector is dominated by large-scale, automated, and regulatory-compliant domestic and multinational players, while the unorganized sector comprises localized, small-scale producers serving regional or unbranded generic and nutraceutical markets. Leading capsule shell and component manufacturers operating within the organized sector include ACG Associated Capsules, the market leader, followed by Erawat Pharma Limited (established 1997, the second-largest capsule manufacturer), Natural Capsules Limited (established 1933), HealthCaps India Ltd., and Sunil Healthcare Limited.

On the finished generic formulation and capsule production side, major players include Sun Pharmaceutical Industries Limited (established 1983, headquartered Mumbai), Dr. Reddy's Laboratories Limited (established 1984, headquartered Hyderabad), and Lupin Limited (headquartered Mumbai). The distribution framework for pharmaceutical capsules operates through a multi-layered channel involving manufacturers to clearing and forwarding agents to super-stockists, then to wholesalers, stockists, retailers, hospitals, and ultimately consumers.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3
• Telemedicine and digital health adoption

<p>The manufacturing technology stack for a generic capsules plant encompasses raw material formulation, shell fabrication, filling, and downstream packaging stages. Raw materials have been evolving from traditional animal-derived gelatin sourced from bovine and porcine skin, bones, and cartilage, toward plant-based alternatives. The principal substitutes are Hydroxypropyl Methylcellulose, a plant-derived cellulose polymer that offers superior moisture stability and lower ingredient reactivity, and pullulan, an organic polysaccharide produced via fermentation of tapioca starch.

Shell fabrication employs high-temperature melting, precision pin-dipping, and double-dipping techniques to produce dual-layer and enteric capsules. The global capsule filling machines market is increasingly dominated by fully automatic machines, which captured the largest market share of 55% in 2025, with hard gelatin capsules leading the capsule type segment at 60% market share. The Asia-Pacific region dominates the pharmaceutical capsule filling machines market globally.

Recent industry developments include Lonza, which operates the Capsugel brand, expanding hard gelatin capsule manufacturing capacity in December 2024 by commissioning additional production lines at its Rewari site in India, and Qualicaps launching next-generation HPMC capsule fillers in May 2025 designed to improve production line efficiency. Capital expenditure for setting up a capsule plant in India varies significantly by scale: a small-scale hard gelatin capsule unit with a single line producing 1 billion to 1.5 billion capsules per year requires a total capital outlay of INR 10 crore to INR 14 crore, with fixed investment at approximately INR 8.13 crore and total project cost including working capital at around INR 9.59 crore based on 2021 estimates. For smaller WHO-GMP compliant generic formulation and capsule manufacturing facilities, investment requirements range from INR 1.5 crore to INR 4 crore.</p>

The Means of Finance recommendation for a generic capsules facility within the ₹9.9-226 crore CapEx band follows a 70:30 debt-to-equity structure at minimum viable scale (₹9.9-25 crore CapEx), transitioning to 60:40 at intermediate scale and 55:45 at premium facilities targeting USFDA certification. This structure aligns with SIDBI's MSME loan eligibility criteria and CGTMSE credit guarantee coverage for the first ₹5 crore of term debt.

SBI capsules loans offer interest rates starting at 9.15% for MSME borrowers with CAG membership or ICICI Bank's SME Premier at 9.25%, both carrying 3-year prepayment penalty windows. HDFC Bank's Business Loan product provides ₹25 lakh to ₹10 crore at 10.25-11.50% without collateral for assets below ₹15 crore, while Axis Bank's Emerging Corporate Loan targets ₹10-50 crore facilities at base rate plus 2.50-3.25%. For the USFDA-certified facility segment, export credit facilities through EXIM Bank's line of credit for pharma machinery (up to 85% of equipment cost at LIBOR plus 2.50%) reduce effective capital cost.

Government scheme optimization is critical. PLI Scheme for Bulk Drugs (Tranche 1 and 2) provides 20-25% production-linked incentive on qualifying capital investments, with the first disbursement typically received 18-24 months post-commissioning. State schemes including Himachal Pradesh's Industrial Investment Policy 2024 (25% capital subsidy capped at ₹2 crore), Telangana's TsHub (50% stamp duty and registration fee refund), and Sikkim's Industrial and Investment Policy 2020 (30% electricity duty exemption for 5 years) materially improve project IRR by 1.5-2.5 percentage points.

Working capital cycle for capsule manufacturing ranges from 55-70 days, driven by 30-45 day gelatin inventory norms (to ensure moisture content stability at 45% RH storage) and 25-35 day finished goods pipeline at distributor warehouses. KAMRIT recommends a revolving credit facility of ₹3-5 crore for every ₹10 crore of annual revenue to cover peak season inventory build (Q3 and Q4 account for 65% of annual sales).

Debt service coverage ratio targets should be maintained above 1.35x throughout the loan tenor, with sensitivity analysis demonstrating DSCR resilience through 15% revenue decline scenarios at the base CapEx level. Break-even occupancy for a 100 million capsule facility ranges from 45-55% of capacity, achievable within 18-24 months of commissioning given the fragmented SME demand for contract capsule manufacturing.

<p>Investors and operators of a generic capsules plant in India must navigate several material risks. First, raw material cost volatility presents a significant operational challenge: gelatin production costs are directly linked to bovine and porcine commodity prices, and the profitability of hard gelatin capsules is extremely sensitive to supplier pricing changes measured in fractions per thousand capsules, resulting in gross profit margins that typically range only between 8% and 12%. Second, regulatory compliance risk remains elevated, as the sector is governed by stringent requirements under the Drugs and Cosmetics Act of 1940, Schedule M of the Revised Good Manufacturing Practices, WHO-GMP standards, and BIS product certification, with non-compliance potentially resulting in manufacturing license suspension.

Third, competitive concentration poses a risk for new entrants, as ACG Associated Capsules commands a dominant position with capacity exceeding 100 billion to 240 billion capsules annually, while multinational players such as Lonza, Qualicaps, and Catalent continuously invest in capacity expansion, as evidenced by Lonza's December 2024 expansion at its Rewari site. Fourth, the unorganized sector, comprising localized small-scale producers, creates downward pricing pressure and can erode margins for commodity-grade gelatin capsule manufacturers. Fifth, the structural shift toward HPMC and plant-based capsules, while an opportunity for some, represents a technology and capital upgrade risk for plants built exclusively for gelatin-based production, as non-gelatin formats grow at 10.25% and are projected to continue displacing conventional products.

Sixth, environmental sustainability commitments are tightening: industry leaders such as Lonza and Capsugel have publicly committed to reducing Scope 1 and Scope 2 emissions by more than 40% by the end of 2030 with a net-zero target by 2050 or earlier, and investors should factor increasing regulatory and reputational pressure to adopt renewable energy initiatives. Seventh, workforce management risk is notable, as production operations require approximately 60% to 75% skilled and technical staff, including machine operators, quality control analysts, and industrial mechanics, to maintain GMP compliance, making talent availability and retention a persistent operational challenge.</p>